Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Health Condition 2: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
Conditions
Interventions
Intervention1: Telemedicine and digital health records: In the intervention arm, the transplant team will additionally communicate with patients via NDHM based telemedicine to ensure adherence to heal
Sponsors
American Society of Hematology
Eligibility
Inclusion criteria
Inclusion criteria: (1) all adults (Age >= 18 years at the time of transplant), (2) all types of transplant (autologous/ allogeneic, irrespective of graft source or conditioning regimen), (3) survival 100 days after most recent HCT with no evidence of relapse, disease progression on the last follow-up, and (4) consent to be approachedusing the NDHM interface
Exclusion criteria
Exclusion criteria: Exclusion criteria will include (1) patients with non-availability of smart-phone based internet services, (2) evidence of disease relapse or progression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) vaccination initiation at day+180 post HCT, (2) bone-health surveillance [DXA scan] and (3) cardio-metabolic surveillance at day+100 post HCT.Timepoint: [3-9 months after the study intervention] | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine (1) Healthcare resource utilization by one-year [scored based on the frequency of contact with a family practitioner, specialist or transplant team visit], (2) Change in HR-QoL at one-year using regional language validated Functional Assessment of Cancer Therapy - Bone Marrow Transplantation [FACT-BMT (12)]and Patient-Reported Outcomes Measurement Information System Global Health [PROMIS-GH(13)] questionnaires administered at scheduled in-person visit or telemedicine(14), (3) Document reasons for non-adherence (financial reasons, lack of time, poor understanding of test importance, non-availability of tests/ caregiver, not communicated by the clinician) and time delay (days) in adherence since the recommended time point, (4) Any intervention subsequent to recommended surveillance results (Anti-resorptive therapy, lipid-lowering agents, anti-hypertension drugs, drugs to control blood glucose, thyroid supplements, etc)Timepoint: [from baseline to 9 months after study intervention] | — |
Countries
India
Contacts
Public ContactDEEPESH LAD
PGIMER, Chandigarh
Outcome results
None listed